WallStSmart
AXSM

Axsome Therapeutics Inc

NASDAQ: AXSM · HEALTHCARE · BIOTECHNOLOGY

$183.95
-0.57% today

Updated 2026-04-29

Market cap
$9.46B
P/E ratio
P/S ratio
14.82x
EPS (TTM)
$-3.68
Dividend yield
52W range
$96 – $193
Volume
0.6M

Axsome Therapeutics Inc (AXSM) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
3 of 8
Last 8 quarters
Avg EPS surprise
+4.8%
Last 4 quarters
Revenue YoY growth
+65.0%
Most recent quarter
EPS YoY growth
+63.6%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
-2.3%
Last 3 reports
Positive reaction rate
33%
1 of 3 quarters
Largest single-day move
-7.5%
2026-02-23
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-02-23$-0.56+22.8%$183.72$169.95-7.5%
2025-11-03$-0.95-11.8%$134.99$134.93-0.0%
2025-08-04$-0.97+8.5%$103.02$103.59+0.6%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$-0.73$-0.56+22.8%$196.00M+65.0%
2025-09-30$-0.85$-0.95-11.8%$170.99M+63.2%
2025-06-30$-1.06$-0.97+8.5%$150.04M+72.1%
2025-03-31$-1.21$-1.22-0.5%$121.46M+62.0%
2024-12-31$-1.00$-1.54-53.6%$118.77M+66.0%
2024-09-30$-1.41$-1.34+4.8%$104.76M+81.3%
2024-06-30$-1.33$-1.67-25.6%$87.17M+86.7%
2024-03-31$-1.20$-1.44-20.0%$75.00M
2023-12-31$-1.17$-2.08-77.8%$71.53M
2023-09-30$-1.20$-1.32-10.0%$57.79M
2023-06-30$-1.22$-1.54-26.2%$46.70M

Frequently asked questions

Has Axsome Therapeutics Inc beaten earnings estimates?
Axsome Therapeutics Inc has beaten Wall Street EPS estimates in 3 of its last 8 quarterly reports, with an average EPS surprise of +4.8% over the last 4 quarters.
How does AXSM stock react to earnings?
AXSM stock has moved an average of -2.3% in the trading day following earnings over its last 3 reports, with positive reactions in 33% of those quarters.
What is Axsome Therapeutics Inc's revenue growth rate?
Axsome Therapeutics Inc reported year-over-year revenue growth of +65.0% in its most recent quarter, with EPS growing +63.6% year-over-year.